Press Releases

 
Press Releases
  Date Title View
Jan 5, 2017
BERKELEY, CA -- (Marketwired) -- 01/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage biopharmaceutical company, today announced that it is reshaping its strategy and operations to prioritize its emerging clinical and preclinical immuno-oncology portfolio. The company has implemented significant organizational restructurin...
Dec 5, 2016
BERKELEY, CA -- (Marketwired) -- 12/05/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2, two-part clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lymphoma. The combination of intratumoral SD-101 and low-dose irradiation resulted in tumor regr...
Dec 1, 2016
BERKELEY, CA -- (Marketwired) -- 12/01/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Inv...
Nov 30, 2016
BERKELEY, CA -- (Marketwired) -- 11/30/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data from a Phase 1/2 clinical trial evaluating its immuno-oncology product, SD-101, in patients with low-grade, B cell lymphoma. The poster presentation will be made at the 58th American Society of Hematology (...
Nov 14, 2016
BERKELEY, CA -- (Marketwired) -- 11/14/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for immunization ...
Nov 9, 2016
BERKELEY, CA -- (Marketwired) -- 11/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. Early results investigating 13 patients with m...
Nov 7, 2016
BERKELEY, CA -- (Marketwired) -- 11/07/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter and nine months ended September 30, 2016. The Company had $109.6 million in cash, cash equivalents and marketable securities as of September 30, 2016, compared to $196.1 million at December 31...
Oct 27, 2016
BERKELEY, CA -- (Marketwired) -- 10/27/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has entered into a note purchase agreement with one or more funds of Deerfield Management Company, L.P, pursuant to which Dynavax has agreed to sell, and Deerfield has agreed to purchase, $100 million principal amount of Dynavax's 1...
Oct 26, 2016
BERKELEY, CA -- (Marketwired) -- 10/26/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced sub-group results from HBV-23, the pivotal Phase 3 trial of its investigational hepatitis B vaccine HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)]. The new subgroup analysis demonstrated that HEPLISAV-B, when administere...
Oct 9, 2016
BERKELEY, CA -- (Marketwired) -- 10/09/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with Keytruda ® (pembrolizumab), Merck's anti-PD-1 treatment. Early results evaluating five patients wi...
FirstPrevious
2
...
NextLast
= add release to Briefcase